AEB-071 Ameliorates Muscle Weakness by Altering Helper T Lymphocytes in an Experimental Autoimmune Myasthenia Gravis Rat Model

AE 1 Feng Jing
BC 1 Wei Huang
BC 1 Qian Ma
BC 1 Sheng-jie Xu
BC 2 Chang-jin Wu
BC 2 Yu-xiu Guan
A 1 Bing Chen

Corresponding Author: Bing Chen, e-mail: chenbing309@sina.cn

Source of support: This study was funded by the 8th Medical Center of Chinese PLA General Hospital

Background: Myasthenia gravis (MG) is an autoimmune neurological disorder of neuromuscular junctions. In this study we established experimental autoimmune myasthenia gravis (EAMG) rat models to investigate the effects of AEB-071 (AEB), which is a specific inhibitor of protein kinase C that prevents T lymphocyte activation.

Material/Methods: We utilized animals divided into 4 groups: (1) control rats, (2) EAMG, (3) AEB-071+EAMG, and (4) AZP+EAMG. Drug treatment was continued for 10 days. Ten weeks after immunization we measured body weights, assessed mortality rates, and used Lennon scores to evaluate EAMG grades. We also assessed the proportions of T_{reg}, T_{h1}, T_{h2}, T_{h17}, and lymphocytes using flow cytometry.

Results: In the absence of drug treatment, we found a significant decline in body weights in the EAMG group in comparison to control rats, and EAMG group rats also had higher Lennon scores (P<0.05). Interestingly, we found that AEB-071 restored the body weight of EAMG rats and the decreased mortality rate compared to AZP treatment. Although a decrease in the number of T_{reg} cells was observed, the proportion of T_{h} lymphocytes was significantly increased in the EAMG group, and AEB-071 treatment decreased the proportion of T_{h} lymphocytes.

Conclusions: We concluded that AEB-071 treatment imparts beneficial effects in EAMG rat models by reducing mortality rate and restoring T_{h} lymphocyte balance, and thus may be an attractive candidate for use in MG treatment.

MeSH Keywords: Autoimmune Diseases • Myasthenia Gravis • Neurology

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/924393
**Background**

MG is an autoimmune neurological disorder of neuromuscular junctions. It is a T-cell-dependent and B-cell-mediated disorder caused by antibodies targeting the neuromuscular junction, primarily the acetylcholine receptor (AChR) [1]. Despite extensive research in the field, the exact pathogenesis of MG remains unclear [2]. MG leads to cellular immune abnormalities mediated by CD4⁺ T lymphocytes [3]. Native CD4⁺ helper T lymphocytes (T₄₁, T₄₂, and T₄₁₇ subsets) [4] are elevated in MG [5] and are correlated with higher AChR antibody titers [6]. In addition, T₄_reg lymphocytes inhibit activation of B cells and T cells to maintain immune homeostasis [7]. A loss of active T₄_reg cells increases susceptibility to autoimmune diseases, as observed in MG [8,9]. Cumulatively, imbalances of Th17, T₄_reg and T₄₁₇ lymphocytes mediate MG progression [10].

Protein kinase C (PKC) is a serine/threonine kinase that regulates a wide range of biological processes, including T cell activation and the downstream signaling of CD28 and T cell receptors [11]. PKC inhibition has been proposed as a therapeutic strategy to treat autoimmune diseases [12]. AEB-071 (AEB, Sotrastaurin) has previously been shown to inhibit the activity of PKC isozymes [13] and thus holds promise for the treatment of T-cell-associated disease. AEB-071 also has the potential to prevent allograft rejection and reduce the inflammatory response [14]. AEB-071 has been shown to have curative effects on psoriasis and autoimmune diabetes [15,16]. However, the role of AEB-071 in MG treatment remains unknown. Azathioprine (AZP) is an oral immunosuppressive drug commonly used in clinical practice. AZP is a pro-drug that is converted in vivo to 6-mercaptopurine (6-MP), which is subsequently metabolized to the pharmacologically active form of 6 thioguanine nucleotides (6-TGN). These metabolites of AZP conjugate with ribose and act as nucleoside monophosphate analogs, thereby inhibiting DNA replication in lymphocytes [17,18]. AZP has been used as a traditional immunosuppressive agent to compare the efficacy and adverse effects of the new immunosuppressive agent AEB-071. In the present study, we treated autoimmune myasthenia gravis rat models (EAMG) with AEB-071 to investigate the underlying therapeutic effects as the basis of a novel treatment for MG.

**Material and Methods**

**Animal models**

Female Lewis rats (6–8 weeks of age) were used to establish the EAMG model according to a previously described protocol [19]. Rats were purchased from the Vital River Laboratory Beijing (SCXK, Beijing, 2012-0001), and average weights were recorded. Animals were maintained in the Experimental Animal Center of the 8th Medical Center of Chinese PLA General Hospital, with 3 animals per cage. Feeding and handling in SPF-class facilities was performed at 23±1°C and 50–70% humidity with a light cycle of 12 h and free access to water and food. All experiments were approved by the Institutional Animal Care and Use Committee of PLA General Hospital and were conducted following its guidelines. The license number was SCXK (Beijing) 2012-0023.

**Reagents and instruments**

The R97-116 peptide derived from the rat (AChR) subunit was used as an immunogen. The peptide (DGDFAIVKFTKVLLDYTGHI) was obtained from Bankpeptide Technology Co. (Hefei, China) (MW: 2252.57 Da, purity ≥95%). Mycobacterium tuberculosis H37RA powder was purchased from DIFCO (Franklin Lakes, NJ, USA). Freund’s adjuvants were obtained from Sigma (St. Louis, MO, USA.). Rat AChR-Ab ELISA test kits (QS41981) were purchased from Qisong Biotechnology Co. (Beijing, China). Sotrastaurin (AEB-071) was produced by GLPBIO (Montclair, CA, USA). Antibodies (anti-rat CD4-FITC, CD25-PE, and Foxp3-APC), fixation buffer, true-nuclear transcription factor buffer sets, intracellular staining permeabilization buffer, and leucocyte cell activation cocktail were purchased from Bio Legend, Inc. Erythrocyte Lysis Buffer and rat interleukin (IL)-17A-APC were purchased from ebioscience, Inc. (San Diego, CA, USA) Azathioprine (AZP) and 0.9% saline (NS) were provided by the Pharmacy Department of the 8th Medical Center of Chinese PLA General Hospital. RPMI-1640 was prepared in-house. The optical density of the test sample and the standard was determined with a Bio-Kinetics microplate reader at a wavelength of 450 nm. Flow cytometry was performed on a BD LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

**Characterization of EAMG models**

EAMG models were established according to previously described protocols [20]. R97-116, CFA, and 0.9% NS solutions (200 µL, ratio: 1: 1.5: 1.5) were added to H37RA (1 mg), which was subcutaneously injected into the footpad, back, and groin of rats. Control rats received 0.9% NS only. Booster immunizations were performed at 30, 45, and 60 days after injection.

**Grouping and drug treatment**

Rats were randomly divided into 4 groups (n=10 per group): the Control group, in which control rats were treated with 0.9% NS orally; the EAMG group, in which EAMG rats were treated with 0.9% NS orally; the AEB-071+EAMG group, which received 30 mg/kg AEB-071 per day by gavage 15 days after EAMG immunization in accordance with previous studies [14,16]; and the AZP+EAMG group, which received the AZP (25 mg/kg) per day orally 15 days after EAMG immunization. The concentration...
of AEB071 was based on previous experiments [21]. The AZP manual recommends a concentration of 1–3 mg/kg, which was calculated based on the conversion ratio from human to animal dosage. A gavage needle was used for intragastric administration. Drug trials lasted for 10 days.

**Clinical evaluations**

Clinical evaluation was performed using Lennon scales according to the EAMG Clinical Rating Scale [22]. This was defined as: 0: no weakness; Grade 1: mild weakness, easy fatigue, especially after repeated grasping; Grade 2: obvious weakness symptoms, tremor, posture change, weak grip; Grade 3: serious muscle weakness, unable to grasp, moribund state; Grade 4: death. Rats showing severe muscle weakness or Lennon scores ≥Grade 3 were humanely sacrificed. After initial immunization, we blindly observed the clinical symptoms of disease, and body weights were assessed on a weekly basis to investigate health status.

**ELISA for serum Anti-AChR antibody assay**

The AChR antibody in the serum was used to assess the successful establishment of the EAMG animal model. A commercial rat AChR antibody ELISA kit was used to determine serum antibody titers. The ELISA kit was provided with a set of standards for establishing a curve for determination of absolute AChR antibody concentration in serum. Blood was obtained from the ocular veins of sacrificed rats and centrifuged for serum collection. Serum was diluted into assay plates (50 μL/well, 60 min) and incubated with enzyme-conjugated antibodies for 30 min at room temperature. Chromogenic reagent was then added for 20 min followed by stop solution (1M H₂SO₄) to terminate the reactions (50 μL). The optical density of the test sample and the standard was determined with a microplate reader at a wavelength of 450 nm.

**Flow cytometry analysis**

\( \frac{T_{reg}}{T_h} \) lymphocyte ratio and the total number of CD4+ T cells in the blood samples were measured. T helper cells were collected after drug intervention, washed in cytological washing solution (PBS+1% FBS), and centrifuged. Cells were labeled with anti-CD4-FITC and anti-CD25-APC antibodies in PBS+1% FBS for 20 min at room temperature and resuspended in permeabilization buffer. Cells were subsequently labeled with fluorescently-conjugated anti-IFN-γ PE for Th1 detection, anti-IL-4 PE for Th2 detection, and IL-17A PE for Th17 detection for 30 min at room temperature. Cells were washed in permeabilization buffer, resuspended in PBS+1% FBS, and analyzed by flow cytometry. For \( T_{reg} \) lymphocyte detection, cells treated as above were labeled with anti-CD4-FITC and anti-CD25-APC antibodies, washed, and labeled in FOXP3 staining solution for 60 min in the dark. Cells were then washed, resuspended in PBS+1% FBS, and analyzed by flow cytometry.

**Statistical analysis**

SPSS statistical software (SPSS, Chicago, IL, USA) and GraphPad Prism 7.0 (GraphPad, San Diego, CA, USA) were used for the statistical analysis. Data are shown as the mean ±standard deviation. All experiments were carried out at least 3 times. The data of the 2 groups were assessed using the t test. Differences between various groups were analyzed by one-way analysis of variance (ANOVA) and followed by Tukey’s multiple comparisons test. A threshold of \( P<0.05 \) was used to indicate statistical difference.

**Results**

**Assessment of clinical symptoms, body weight and Lennon score**

Two weeks after R97-116 inoculation, the EAMG group showed muscle weakness and significant weight loss. The animals exhibited dull coats and listlessness. Focal inflammatory response was present at the injection sites. EAMG rats also showed hypo-activity, including reduced crawling and grip, weak bite and vocalization, and weakness aggravated by activity. EAMG rats also showed decreased appetite, reduced food intake, and weight loss. Ten weeks after immunization, the EAMG group had higher Lennon scores than the control group, as shown in Figure 1A. The body weights of EAMG rats (179.68±8.59) were significantly lower compared to the control group (238.63±7.46) (\( P<0.05 \)) (Figure 1B). MG is a disease with unknown etiology and diverse pathogenesis, which eventually results in dysfunction of neuromuscular junction transmission due to production of autoantibodies to AChR. To confirm EAMG, serum anti-AChR was assessed using ELISA (Figure 1C). ELISA results showed that the level of serum anti-AChR in the EAMG group was higher (\( P<0.05 \)). These results show the successful establishment of the EAMG model.

**AEB-071 improved the clinical symptoms of EAMG**

In animal models of AEB071 intervention, the experimental period is typically short (typically less than 30 days). In our models, we observed that the symptoms of weakness and local inflammation in rats were significantly improved after about 10 days of intervention. Thus, the experiment was terminated after 10 days. Rats in the AEB-071+EAMG and AZP+EAMG groups showed fewer MG symptoms than the EAMG group. The body weights of rats in the AEB-071+EAMG, AZP+EAMG, EAMG, and control groups were 212.62±7.63, 189.95±9.86, 172.53±13.57, and 247.52±10.66, respectively (Figure 2A),
indicating the restoration of body weight in response to AEB-071 treatment. The Lennon scores of the AEB-071+EAMG, AZP+EAMG, and EAMG groups were (1.56±0.43, 3.06±1.67, and 3.52±0.93), respectively. There was a significant decrease in local inflammatory response with the AZP and AEB-071 treatment, associated with slowed onset of disease and alleviation of symptoms of EAMG (Figure 2B). Lower Lennon scores and higher body weights suggested the curative effect of AEB-071 and AZP. Also, ELISA results showed that AEB-071 treatment decreased the level of serum anti-AChR in EAMG rats (Figure 2C). Furthermore, the AEB-071+EAMG group had lower Lennon scores and higher body weights than the AZP+EAMG group (P<0.05). In addition, the mortality rates of the AEB-071+EAMG, AZP+EAMG, and EAMG groups were 20%, 40%, and 70%, respectively, at 10 days after the intervention. The mortality rates were significantly lower in the AEB-071 group compared to the EAMG group (without drug treatment) or AZP+EAMG group. These results suggest that AEB-071 has a better therapeutic effect compared to AZP.

**AEB-071 altered helper T lymphocyte counts in blood of EAMG rats**

On day 10 after treatment, we observed that the proportion of T_{reg} cells was decreased, and the ratios of T_{h1}, Th2, and Th17 cells were increased in the EAMG group compared to the control group (P<0.05). Interestingly, treatment with AEB-071 and AZP decreased the ratios of T_{h1}, T_{h2}, and T_{h17} lymphocytes in the EAMG group (P<0.05). Furthermore, the AEB-071+EAMG group had T_{reg} numbers similar to those in the EAMG group, and the number of T_{reg} cells in the AZP+EAMG group was lower (Figure 3). These results indicated that AEB-071 intervention significantly reversed the T cell subtype imbalance induced by EAMG in rats, and the effect was better than that of AZP.

**Discussion**

The equilibrium of T_{reg} and T_{h} cells is critical for immune homeostasis, and an alteration in the equilibrium leads to autoimmune diseases such as MG. CD4^+ helper T cells are important T cell subtypes that exhibit distinct cytokine secretion...
patterns. For example, T\(_1\) lymphocytes secrete IFN-\(\gamma\), which is increased in EAMG models and enhances the severity of MG [23]. Also, T\(_2\) cells have been shown to secrete IL-4 and IL-6, induce B cell growth and differentiation, and enhance production of T\(_{17}\). T\(_{17}\) lymphocytes have been found to secrete IL-17, a pro-inflammatory cytokine [24], the levels of which are enhanced in MG and are correlated with anti-AChR titers [6,25]. Imbalances in helper T cells and T\(_{reg}\) lymphocytes induce MG [26]. In this study we observed an increased proportion of T\(_1\), T\(_2\), and T\(_{17}\) lymphocytes in EAMG and decreased T\(_{reg}\) lymphocyte numbers, in agreement with previous reports [3]. Dysregulated numbers of CD4\(^+\) helper T cells have been linked to a loss of immune balance [26,27] as reported in multiple sclerosis, systemic lupus erythematosus, and MG [26–28]. Restoring this balance offers a viable way to treat MG [29]. The prevalence of T cells in peripheral tissues can be highly variable, and both memory T cells and T\(_{reg}\) can be resident in specific tissues, with these tissue-resident lymphocytes playing important roles in maintaining immune homeostasis and in autoimmunity [30]. The tissue distribution and inhibitory effect on these lymphocyte populations in neuromuscular tissues may be critical for the efficacy of AEB071 and for the activity observed in this study.

PKC signaling regulates an array of cellular processes, including T cell activation [31], and is crucial for T\(_2\) and T\(_{17}\) lymphocyte differentiation [32,33]. The general consensus is that PKC\(\theta\) positively regulates T\(_1\), T\(_2\), and T\(_{17}\) lymphocyte functions [34] and is highly expressed in immunological and inflammatory disorders [35]. However, PKC\(\theta\) negatively regulates T\(_{reg}\) function [36], suggesting that it can promote T cell imbalances. The restriction of positive regulation by PKC\(\theta\) through an...
NFκB-activating complex to effector T cells may explain the lack of effect on Treg numbers by AEB071 in the present study [37].

AEB-071 is a selective PKC inhibitor with strong activity against PKCδ, α, and β isoforms [38]. AEB-071 can prevent allograft rejection and reduce inflammatory responses [14] and has been assessed as an immunosuppressant during renal and liver transplantation in clinical trials [39]. In this study, we investigated the effects of AEB-071 on MG disease progression. EAMG rats showed an increase in weight and reduced muscle weakness in response to AEB-071 treatment. Attenuation of focal inflammation was also observed. These results indicated that AEB-071 inhibits autoimmune disease and inflammatory responses. In the AEB-071 group, T_1, T_2, and T_17 lymphocyte ratios were decreased, while T_reg levels showed no significant decrease. These results indicated that AEB-071 restores T_b lymphocyte balance, with clear therapeutic potential for MG treatment. In the AZP group, MG symptoms and focal inflammation were also reduced, highlighting its therapeutic effects. However, AZP has a different mechanism of action than AEB-071. AZP is a non-specific immunosuppressant that interferes with DNA synthesis, leading to a decline in T_n and T_reg cell proportions in the peripheral blood. Despite the improved symptoms, rats in the AZP group showed increased weight loss, increased Lennon scores, and higher mortality rates compared to the AEB-071 group, indicating a lower efficacy of AZP compared to AEB-071.

PKC has been shown to activate B lymphocytes [40], while its inhibition results in decreased B cell proliferation. AEB-071 also has shown promising curative effects in B cell lymphoma [41]. Therefore, we speculated that in addition to regulating cellular immunity, AEB-071 inhibits humoral immunity and antigen presentation through its ability to inhibit B cells via PKC inhibition. This may underlie its effectiveness in the treatment of MG disease. In addition to its role in the regulation of lymphocyte activation and proliferation, PKC may also regulate the differentiation of embryonic muscles [42]. We observed minimal levels of muscle atrophy in AEB-071-treated rats, although conclusions regarding long-term atrophy effects cannot be drawn from the present results. PKC has been shown to participate in embryonic myoblast differentiation but not fetal myoblast differentiation [42]. Based on our data, we speculate that use of AEB-071 will not lead to significant muscle atrophy in the short term; however, its impact during prolonged treatment needs further investigation. While we did not evaluate adverse effects that may be associated with longer-term use of AEB071, which can include bone marrow suppression, liver damage, and carcinogenesis, we generally observed a lack of known possible short-term adverse effects, including gastrointestinal symptoms. We also observed the general health of mice under treatment by assessment of posture and behavior and measured body weight, showing that general health was significantly improved in EAMG rats treated with AEC071 compared to the control rats and untreated EAMG rats, and treated animals did not display signs of general adverse effects.

Our literature search found no reports on the application of AEB-071 or other protein kinase C inhibitors in treatment of myasthenia gravis (MG). Therefore, the effect of these drugs on MG has been previously unknown. The purpose of this study was to explore the short-term therapeutic efficacy and toxicity of AEB-071 in a rat model of MG. While the scope of the present study does not address the underlying mechanism, we clearly demonstrated effective short-term amelioration of symptoms in a relevant model of MG with AEB071 treatment. As a first step in establishing the phenotypic and clinically relevant effects of the drug, these results justify further in-depth mechanistic studies, including those regarding PKC inhibition using these models in future studies.

There were some limitations to this study. First, we only observed the short-term curative effects of AEB-071 (the observation period was only 10 days), meaning no rats were completely cured and the Lennon scores remained high after drug intervention. Improved curative effects may be detected with extended observation periods. The long-term safety and efficacy of this compound requires further investigation. Also, this was a preliminary study on the use of AEB-071 to treat MG. We only focused on the curative effects and drug safety and assessed T lymphocyte frequency to explore potential mechanisms. Changes in AChR antibodies and muscle and thymus histopathology were not assessed. We therefore could not discount alternative therapeutic mechanisms. Future studies in this area are required. Finally, the sample size was relatively small. While the numbers were sufficient for confidence in the results we have reported, larger numbers will be needed to evaluate rarer adverse effects, long-term effects, and the mechanism, which will be the subjects of further research. The scope of this study was limited to the cellular level. Further research on interleukin levels and effector proteins are warranted to clarify the mechanism of action.

**Conclusions**

In summary, our results indicate that AEB-071 shows minimal adverse effects and superior beneficial effects in EAMG rat models. Therefore, AEB-071 may be a candidate as an effective treatment for MG. Compared to AZP, AEB-071 showed significantly lower mortality and Lennon scores and improved body weight, indicating its superiority to AZP in the treatment of EAMG. Further investigations regarding the mechanism may provide new avenues for MG treatment.
Acknowledgments

We are grateful for help from Dr. Ying-chang Shi and Dr. Li Li from the Animal Center of the 8th Medical Center of Chinese PLA General Hospital.

References:

1. Behin A, Le Pasre R: New pathways and therapeutic targets in autoimmune myasthenia gravis. J Neuroimmunol, 2018; 303: 265–77
2. Meng GF, Zhang Z, Wang YJ et al: Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells. J Neuroimmunol, 2016; 298: 138–45
3. Jing F, Yang F, Cui Z et al: Rapamycin alleviates inflammation and muscle weakness, while altering the Treg:Th17 balance in a rat model of myasthenia gravis. Biorep, 2017; 17(4): BS20170767
4. Ziegler SF: Division of labour by CD4(+) T helper cells. Nat Rev Immunol, 2016; 16(7): 403
5. Berrih-Aknin S, Le Pasre R: Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun, 2014; 52: 90–100
6. Wang Z, Wang W, Chen Y, Wei D: T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol, 2012; 76(1): 54–61
7. Meng X, Yang L, Dong M et al: Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol, 2016; 13(3): 167–79
8. Masuda M, Matsumoto M, Tanaka S et al: Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol, 2010; 225(1–2): 123–31
9. Thiruppattii M, Rowin J, Ganesh B et al: Impaired regulatory function in circulating CD4+CD25(high)CD127(low/−) T cells in patients with myasthenia gravis. Clin Immunol, 2012; 145(3): 209–23
10. Wang Z, Yan Y: Immunopathogenesis in myasthenia gravis and neuromyasthenia optica. Front Immunol, 2017; 8: 1785
11. Gruber T, Pfeifhofer-Oberrair C, Bai R: PKCtheta is necessary for efficient activation of NKp44, NKp30, and NAP-1 during positive selection of thymocytes. Immunol Lett, 2010; 132(1–2): 6–11
12. Miller AT, Dahlberg C, Sandberg ML et al: Inhibition of the inositol kinase Itpkb augments calcium signaling in lymphocytes and reveals a novel strategy to treat autoimmune disease. PLoS One, 2015; 10(6): e0131071
13. Evenou JP, Wagner J, Zenke G et al: The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther, 2009; 330(3): 792–801
14. Fang YH, Joo DJ, Lim JB et al: AEB-071 versus tacrolimus monotherapy to treat severe autoimmune disease. J Autimmune, 2018; 8(3): 265–77
15. Manicassamy S: Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. Curr Opin Investig Drugs, 2009; 10(11): 1225–35
16. Merani S, Edgar RL, Emamaulllee J et al: PKCtheta: A novel drug target for selective immunosuppression. Adv Pharmacol, 2011; 63: 385–413
17. Lennon VA, Lindstrom LM, Seybold ME: Experimental autoimmune myasthenia gravis: A model of myasthenia gravis in rats and guinea pigs. J Exp Med, 1975; 141(6): 1365–75
18. Armstrong VW, Oellerich M: New developments in the immunosuppressive strategy to treat autoimmune disease. PLoS One, 2015; 10(6): e0131071
19. Xie Y, Li H, Jiang B et al: Elevated plasma interleukin-17A in a subgroup of myasthenia gravis patients. Cytokine, 2016; 78: 44–46
20. Mu L, Sun B, Kong Q et al: Disequilibrium of Th1 helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology, 2009; 128(1 Suppl.): S682–36
21. Talaat RM, Mohamed SF, Bassouyihi NH, Raouf AA: Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients. Correlation with disease activity. Cytokine, 2015; 72(1): 146–53
22. Raphaei I, Nalawade S, Eagar TN et al: T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine, 2015; 74(1): 5–17
23. Xie Y, et al. ATRA alters humoral responses associated with amelioration of EAMG symptoms balancing Th17/Tfr helper cell profiles. Clin Immunol. 2013;148(2): 162–76.
24. Kumar BV, Mu L, Yao X et al: Human T cell development, localization, and function throughout life. Immunity. 2018; 48(2): 202–13
25. Wang XD, Gong Y, Chen Z-L et al: TCR-induced sumoylation of the kinase Itpkb augments calcium signaling in lymphocytes and reveals a novel strategy to treat autoimmune disease. PLoS One, 2015; 10(6): e0131071
26. Yang J, Sundrud MS, Skepner J, Yamagata T: Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci, 2014; 35(10): 493–500
27. Wachowicz K, Hermann-Kleiter N, Meisel M et al: Protein kinase C theta regulates the phenotype of murine CD4+ Th17 cells. PloS One, 2014; 9(5): e96401
28. Salek-Ardakani S, So T, Halteman BS et al: Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase C theta. J Immunol, 2004; 173(10): 6440–47
29. Zappelli F, Willems D, Osada S et al: The inhibition of differentiation caused by TGFbeta in fetal myoblasts is dependent upon selective expression of protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol, 2007; 25(13): 1741–46
30. Zanin-Zhorov A, Dustin ML, Blazar BR: PKC-theta function at the immunological synapse: Prospects for therapeutic targeting. Trends Immunol, 2011; 32(8): 358–63
31. Zanin-Zhorov A, Ding Y, Kumari S et al: Protein kinase Ctheta mediates negative feedback on regulatory T cell function. Science, 2010; 328(5976): 372–76
32. Zanin-Zhorov A, Dustin ML, Bazlar BR: PKC-theta function at the immunological synapse: Prospects for therapeutic targeting. Trends Immunol, 2011; 32(8): 358–63
33. Hage-Seiman R, Hamze AB, Reslan L et al: The novel PKCtheta from bench-top to clinic. J Immunol Res, 2015; 2015: 348798
34. Kovarik JM, Slade A: Overview of sotrastaurin clinical pharmacokinetics. Ther Drug Monit, 2004; 26(2): 186–91
35. Armstrong VW, Oellerich M: New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem, 2001; 34(1): 9–16
36. Losen M, Martinez-Martinez P, Molenaar PC et al: Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors – Recommendations for methods and experimental designs. Exp Neurol, 2015; 270: 18–28
37. Baggi F, Annoni A, Ubiali F et al: Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol, 2004; 172(4): 2697–703
38. Fang YH, Joo DJ, Lim JB et al: The effects of AEB071 (sotrastaurin) with tacrolimus on rat heterotopic cardiac allograft rejection and survival. J Surg Res, 2011; 171(1): e133–37
39. Lennon VA, Lindstrom LM, Seybold ME: Experimental autoimmune myasthenia gravis: A model of myasthenia gravis in rats and guinea pigs. J Exp Med, 1975; 141(6): 1365–75
40. Wang HB, Shi FD, Li H et al: Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin Immunol, 2000; 95(2): 156–62
41. Yang J, Sundrud MS, Skeperj J, Yamagata T: Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci, 2014; 35(10): 493–500
42. Zappelli F, Willems D, Osada S et al: The inhibition of differentiation caused by TGFbeta in fetal myoblasts is dependent upon selective expression of PKC-theta. A possible molecule basis for myoblast diversification during limb histogenesis. Dev Biol, 1996; 180(1): 156–64